Emerging Biological Treatments for Uterine Cervical Carcinoma
Patrizia Vici, Luciano Mariani, Laura Pizzuti, Domenico Sergi, Luigi Di Lauro, Enrico Vizza, Federica Tomao, Silverio Tomao, Emanuela Mancini, Cristina Vincenzoni, Maddalena Barba, Marcello Maugeri‐Saccà, Giuseppe V. Giovinazzo, Aldo Venuti · Journal of Cancer · 2014
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · review · 2014
Abstract
Cervical cancer is the third most common cancer worldwide, and the development of new diagnosis, prognostic, and treatment strategies is a major interest for public health. Cisplatin, in combination with external beam irradiation for locally advanced disease, or as monotherapy for recurrent/metastatic disease, has been the cornerstone of treatment for more than two decades. Other investigated cytotoxic therapies include paclitaxel, ifosfamide and topotecan, as single agents or in combination, revealing unsatisfactory results. In recent years, much effort has been made towards evaluating new drugs and developing innovative therapies to treat cervical cancer.
Among the most investigated molecular targets are epidermal growth factor receptor and vascular endothelial growth factor (VEGF) signaling pathways, both playing a critical role in cervical cancer development. Studies with bevacizumab or VEGF receptor tyrosine kinase have given encouraging results in terms of clinical efficacy, without adding significant toxicity. A great number of other molecular agents targeting critical pathways in cervical malignant transformation are being evaluated in preclinical and clinical trials, reporting preliminary promising data.
In the current review, we discuss novel therapeutic strategies which are being investigated for the treatment of advanced cervical cancer.
Open the resolved locator · 10.7150/jca.7963
Metadata licence: OpenAlex metadata (CC0)